Hepatitis C virus core antigen assay: an alternative method for hepatitis C diagnosis
|
|
- Toby Garrett
- 5 years ago
- Views:
Transcription
1 Research Article Annals of Clinical Biochemistry 2017, Vol. 54(2) ! The Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI: / journals.sagepub.com/home/acb Hepatitis C virus core antigen assay: an alternative method for hepatitis C diagnosis Lijuan Wang*, Hong Lv* and Guojun Zhang Abstract Background: The study aimed to evaluate a fully automated chemiluminescent immunoassay and compared it with a quantitative RNA assay and anti-hcv assay to verify the utility of this automated Ag assay as an alternative method for hepatitis C diagnosis. Methods: A total of 229 serum samples previously tested for anti-hcv concentrations by the Architect Anti-HCV assay, were selected for HCV RNA testing by real time RT-PCR kit (Shanghai ZJ Bio-Tec Co., Ltd) and 125 specimens were tested for HCV Ag by the Architect HCV core Antigen kit. Results: The log 10 HCVAg and HCV RNA concentrations were highly correlated [r ¼ 0.834); with HCV RNA as the comparator test, HCVAg had 100% specificity, 100% positive predictive value (PPV) and 94.8% sensitivity. We found 1 pg/ ml of total HCV core Ag is equivalent to approximately 6607HCV RNA international units (IU)/mL. Receiver operator characteristic curve analysis showed that the area under the curve of HCV core Ag (0.989) was greater than HCV Ab (0.871). HCV Ag concentrations and RNA-to-Ag ratio of the groups for HCV RNA concentrations and >10 5 IU/ ml were both significantly different from each other (P < 0.05). Conclusion: The Architect HCV core Ag assay may be an alternative method for hepatitis C diagnosis, performed on the same analytical platform and sample as the anti-hcv assay, shortening the diagnostic window period, demonstrating good correlation with HCV RNA assay with high specificity and positive predictive value. Keywords HCV core antigen, HCV RNA, hepatitis C Accepted: 4th July 2016 Introduction Hepatitis C virus (HCV), a single-strand, positive-sense RNA virus, causes slowly progressive diseases: chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. 1,2 The World Health Organization (WHO) estimates that approximately 170 million people are infected with HCV worldwide, with about 75 80% developing chronic disease. 3 5 Virological diagnosis and monitoring of HCV infection are based on the use of serologic assays detecting specific anti-hcv antibodies. 6 However, HCV RNA detection, viral load qualification and HCVgenotyping are also widely used in clinical practice. 7,8 The anti-hcv assay is simple, inexpensive and rapid as a screening test, but lacks detection sensitivity in the early window period of 45 to 68 days after infection Furthermore, anti-hcv assay is unable to distinguish Department of Clinical Laboratory, Beijing Tiantan Hospital, Capital Medical University, Beijing, China *Co-authors. Corresponding author: Guojun Zhang, Department of Clinical Laboratory, Beijing Tiantan Hospital, Capital Medical University, No. 6, TiantanXili Street, Dongcheng District, Beijing , China. Tiantanzgj@163.com
2 280 Annals of Clinical Biochemistry 54(2) between active infection and past infection. 9 HCV RNA detection techniques are used to overcome this shortcoming. 12 The HCV RNA assay is a reliable method, which has high sensitivity, specificity and low detection limits and can give quantitative results. 13 However, it involves considerable technical skill, high costs and longer turn-around time and may lead to false positive results due to contamination. 4,14 Therefore, the availability of an accurate, simpler and cheaper test would be appealing. Tests for HCV core antigen detection were first reported in the 1990s 15 and the detection effectiveness has improved over the subsequent decades. The majority of the previous assays used enzyme-linked immunosorbent assays (ELISAs) or enzyme immunoassay (EIAs) to detect HCV core Ag. 16 Recently, a fully automated chemiluminescent immunoassay (CLIA) was introduced, which allows for a quantitative determination of HCV core antigen in human serum and plasma. 17 In this study, we aimed to evaluate the CLIA and compare it with a quantitative RNA assay and anti- HCV assay to verify its utility as an alternative test for hepatitis C diagnosis. Methods Patients A total of 229 serum samples were studied, which were derived from the Laboratory diagnosis center of Beijing Tiantan Hospital, Capital Medical University. All samples had been previously tested for anti-hcv concentrations by the Architect anti- HCV assay and were stored at 70 C prior to analysis. Thereafter, all samples were selected for HCV RNA testing of which 125 specimens were tested for HCV Ag. Of the 229 specimens tested, 208 were antihuman immunodeficiency (HIV) negative (21 samples not tested). Measurements The Architect anti-hcv assay. The Architect anti-hcv assay is a two-step immunoassay, using chemiluminescent microparticle immunoassay (CMIA) technology, for the qualitative detection of anti-hcv in human serum and plasma by an Abbott Architect i2000sr analyzer (Abbott Laboratories, Abbott Park, IL, USA) with an HCV Ab assay kit (Abbott Laboratories, Abbott Park, IL, USA). In the first step, sample, recombinant HCV antigen-coated paramagnetic microparticles and assay diluent are combined. Anti-HCV present in the sample binds to the HCV-coated microparticles. After washing, antihuman acridinium-labelled conjugate is added in the second step. Following another wash cycle, Pre-trigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as relative light units (RLUs). AS/CO < 1 means not reactive, and >1 reactive, where S is the signal of the sample and CO is the cut-off control. The quality control material used was Bio-Rad (California, USA) QC level 1: GBW (E) , level 2: GBW (E) The Architect HCV Ag assay. The Architect HCV Ag assay is a two-step immunoassay, using CMIA technology, with flexible assay protocols referred to as Chemiflex, for the quantitative determination of core antigen of HCV by an Abbott Architect i2000sr analyzer (Abbott Laboratories, Abbott Park, IL, USA) with an HCV Ab assay kit (Abbott Laboratories, Abbott Park, IL, USA). In the pre-treatment step, sample, pre-treatment reagent 1 and pre-treatment reagent 2 are combined. An aliquot of the pre-treated sample is aspirated and dispensed into a new reaction vessel. The pre-treated sample, assay-specific diluent and anti- HCV-coated microparticles are combined. HCV Ag present in the pre-treated sample binds to the anti- HCV-coated microparticles in the first step. After washing, acridinium-labelled anti-hcv conjugate is added in the second step. Following another wash cycle, pretrigger and trigger solutions are added to the reaction mixture. The resulting chemiluminescent reaction is measured as RLUs. The cut-off value is 3.0 fmol/l; HCV Ag concentrations below 3.0 fmol/l were therefore considered nonreactive. HCV RNA detection and quantification. Quantitative detection of HCV RNA by real-time polymerase chain reaction (RT-PCR) was performed using the HCV real time RT-PCR kit (Shanghai ZJ Bio-Tec Co., Ltd) according to the manufacturer s instructions on Roche light cycler real-time PCR system (Roche Diagnostics GmbH, Mannheim, Germany). The results were expressed in HCV RNA IU/mL. The lower detection limit is IU/mL. HCV RNA results were accepted as the gold standard when performing the comparisons. The quality control material purchased from Shanghai ZJ Bio-Tec Co., Ltd (Shanghai, China). Statistical analysis Statistical analysis was performed using SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA). The correlation coefficients between HCVAg and HCVRNA were calculated by Spearman s rank test and a comparison between the groups was carried out using the Mann- Whitney U test. A P value of less than 0.05 was considered statistically significant.
3 Wang et al. 281 Results Of the 229 specimens tested, 128 (55.9%) were from men. The age range was 7 to 89 years (median 54.9 years). All specimens were selected for HCV RNA testing and anti-hcv assay, of which 129 (56.3%) were anti-hcv-reactive/hcv-rna-positive and 100 (43.7%) were anti-hcv-positive/hcv-rna-negative (Table 1). HCV core Ag was measured in 125 subjects; among them 7 (5.6%) cases in which HCV RNA was not detected were nonreactive for HCV core Ag. Of the 116 cases in which HCV RNA concentrations exceeded 1000 IU/mL, 115 (99.1%) were reactive for HCV Ag (Table 1). HCV RNA concentration of one RNA-positive/HCV Ag-negative serum sample was 5510 IU/mL. Two serum samples in which HCV core Ag concentrations exceeded 3 fmol/l and were nonreactive for HCV RNA were neurosurgery outpatients. With the HCV RNA assays as the gold standard, the diagnostic sensitivity, specificity, positive and negative predictive values and accuracy rate of HCV core Ag/anti-HCV assay were detected as 94.82%/91.47%, 100%/81.0%, 100%/86.13%, 60%/88.04% and 95.2%/86.9%, respectively (Table 2). ROC analysis indicated that the cut-off value of HCV Ag assay was fmol/l Table 1. HCV Ab, HCV Ag and HCV RNA test results. HCV RNA (IU/mL) HCV Ab (S/CO) Table 2. The diagnostic efficacy evaluation of HCV Ag and HCV RNA assay for hepatitis C. HCV Ag HCV Ag (fmol/l) >1 <1 >3 <3 > < HCV Ab AUC Cut-off point P <0.001 <0.001 Sensitivity (%) Specificity (%) Accuracy (%) Diagnostic index PPV (%) NPV (%) Note: The HCV RNA assay was used as the gold standard. AUC: area under the curve; PPV: positive predictive value; NPV: negative predictive value and anti-hcv assays S/CO cut-off value was 11.65, with an area under curve of and 0.871, respectively, P < 0.05 (Figure 1). Figure 2 shows the correlation between HCV core Ag and RNA concentrations (r ¼ 0.834; 95% confidence interval [CI], to 0.881; P < 0.001). A regression analysis of the 125 specimens yielded the equation y ¼ , where y is the concentration of HCV Ag in log 10 fmol/l, and x is the concentration of HCV RNA in log 10 IU/mL. Based on this equation, it was possible to calculate that 1 pg/ml of total HCV core Ag is equivalent to approximately 6607 IU/mL. In the 125 HCV RNA and HCV core Ag detected cases, the group classifications were arbitrarily made by use of HCV RNA concentrations of and >10 5 IU/mL. Median HCV core Ag concentrations of those groups were and fmol/l, respectively, and there were significant differences between them (Figure 3, P < 0.001). Figure 4 shows that the median values of the RNA-to-Ag ratio in the groups of RNA concentrations 4105 and >105 IU/mL were and kiu/ml, respectively, and significant differences between them were also noted (P ¼ 0.006). Discussion Hepatitis C remains a major health care burden globally with a high prevalence in developing countries. 14 Intravenous drug use, blood transfusion and haemodialysis are major risk factors for the spread of HCV Thomas et al. 21 have shown that an increasing number of people living with human immunodeficiency virus (HIV) are co-infected with the HCV. HIV co-infection complicates the course of hepatitis C with subjects more likely to develop cirrhosis over a shorter period of time. 22 Furthermore, co-infection with HCV may lead to a more rapid progression to acquired immune-deficiency syndrome (AIDS). 23 There is therefore a need for early HCV diagnosis in HIV patients so that optimum treatment may be offered. Anti-HCV testing is a commonly used screening test for HCV infection, but which is not sensitive and does not discriminate active from past infection. Although HCV RNA testing has been recommended to confirm active infection, its use in clinical practice has been limited by the expensive and time-consuming nature of the assay and the high degree of technical expertise required. For these reasons, HCV core Ag testing has been extensively used, as it was considered to be quick, simple, less expensive and cost-effective. Aghemo et al. 24 demonstrated that measurement of HCV core Ag can be used to monitor the efficacy of direct-acting antiviral (DAA) therapy for HCV infection. Moreover, Florea et al. 9 showed that HCV core Ag assay may diagnose active HCV infection.
4 282 Annals of Clinical Biochemistry 54(2) Figure 1. ROC analysis illustrating that the detection efficacy of HCV core Ag was better than HCV Ab for hepatitis C (AUC ¼ > 0.871, P < 0.05). Figure 2. Correlation between HCV Ag and HCV RNA concentrations. The concentrations of HCV Ag were highly correlated with those of HCVRNA by Spearman s rank correlation test (r ¼ 0.834, P < 0.05).
5 Wang et al. 283 Figure 3. HCV Ag concentrations grouped by HCV RNA concentrations. Median HCV core Ag concentrations were and fmol/l for the groups of RNA concentrations and >10 5 IU/mL respectively and there were significant differences between them (P < 0.05). Figure 4. RNA-to-Ag ratio accordingly grouped by HCV RNA concentrations. The RNA-to-Ag ratios of the groups of RNA concentrations and >10 5 IU/mL were significantly different from each other (P < 0.05).
6 284 Annals of Clinical Biochemistry 54(2) The present study found a good correlation between HCV RNA and HCV core Ag concentrations (correlation coefficient ¼ 0.834) which was in keeping with other studies comparing the Architect HCV core antigen test with a range of HCV RNA measurement methods and which found correlation coefficients in the range to ,25 27 A previous study also found a strong correlation (r ¼ 0.864) between the HCV Ag and HCV RNA as measured by the Qiagen HCV RNA tes (Quiagen, Hilden). 10 Using HCV RNA assay as the gold standard, the receiver operator characteristic (ROC) curve analysis showed the area under the curve of HCV core Ag (0.989) is greater than HCV Ab (0.871) indicating that the detection efficacy of HCV core Ag was better than HCV Ab. The specificity and positive predictive values were both 100% with a sensitivity was 94.82%, in keeping with previous studies. 1,10 Our finding of a negative predictive value of 60% (lower than that reported in previous studies) means that negative results should be confirmed by HCV RNA testing. Our results showed large fluctuations in HCVRNA/ core Ag ratio ranging from to 70, kiu/fmol, but increased as the concentration of RNA increased. In the present study, 1 pg/ml of total HCV core Ag is equivalent to approximately 6607 IU/mL RNA. In previous reports, the 1 pg/ml HCV core Ag equivalent has varied between 428 and 8000 IU/mL RNA. 6,11,27,28 In one of the two studies it was investigated that HCV genotype was found to have an effect on the HCV RNA/core Ag equivalence value. 27,28 Other possible reasons for differences in the equivalence values between different studies may include differences between assays and differences between subjects; this requires further investigation. The present study has several limitations. Firstly, the study was conducted using anti-hcv antibody-positive serum only and we were uncertain whether early HCV infection in antibody-negative subjects could be detected by the HCV core Ag assay. Secondly, the limit of detection of the HCV RNA assay was 1000 IU/mL and lower than that used by other investigators, which may have resulted in differences in sensitivity, specificity, PPV and NPV of the HCV Ag assay. In summary, the Architect HCV core Ag assay showed a good correlation between the logarithmic values of HCV RNA and HCV Ag (r ¼ 0.834), with 100% specificity and PPV, and 94.82% sensitivity. Moreover, HCV core Ag testing can use the same platform and sample with anti-hcv assay, which is simpler, faster and more convenient than the HCV RNA tests. Acknowledgement Lijuan Wang thanks Hong Lv and Guojun Zhang who have supported the author with sincere gratitude. Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) received no financial support for the research, authorship, and/or publication of this article. Ethical approval Not required. Guarantor GZ. Contributorship All three authors contributed to the design of the study. LW researched the literature, wrote the first draft of the paper and edited the final manuscript. GZ was responsible for the overall design of experiments and performed all statistical analyses. HL was responsible for the initial data acquisition and also contributed to the first draft of the paper. All authors agreed with the final draft of the manuscript. References 1. Park Y, Lee JH, Kim BS, et al. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010; 48: Aoyagi K, Ohue C, Iida K, et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37: Vine LJ, Sieberhagen C and Cramp ME. Diagnosis and management of hepatitis C. Br J Hosp Med 2015; 76: Morota K, Fujinami R, Kinukawa H, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Meth 2009; 157: Wasley A and Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liv Dis 2000; 20: Bouvier-Alias M, Patel K, Dahari H, et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36: Villar LM, Cruz HM, Barbosa JR, et al. Update on hepatitis B and C virus diagnosis. World J Virol 2015; 4: Pawlotsky JM. Diagnostic tests for hepatitis C. J Hepatol 1999; 31(Suppl 1): Florea D, Neaga E, Nicolae I, et al. Clinical usefulness of HCV core antigen assay for the management of patients with chronic hepatitis C. J Gastroint Liv Dis: JGLD 2014; 23: Kesli R, Polat H, Terzi Y, et al. Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-hcv results. J Clin Microbiol 2011; 49: Glynn SA, Wright DJ, Kleinman SH, et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005; 45: Chakravarti A, Chauhan MS, Dogra G, et al. Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings? Braz J Infect Dis 2013; 17: Kadkhoda K and Smart G. HCV antigen testing for the diagnosis of hepatitis C infection: a cost-efficient algorithm. Clin Lab 2014; 60: Soliman HA, Hozayen WG, Mahmoud AM, et al. Significance of the hepatitis C virus core antigen testing as an alternative marker for hepatitis diagnosis in Egyptian patients. Eur Rev Med Pharmacol Sci 2015; 19: Tanaka T, Lau JY, Mizokami M, et al. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J Hepatol 1995; 23: Buket CA, Ayse A, Selcuk K, et al. Comparison of HCV core antigen and anti-hcv with HCV RNA results. Afr Health Sci 2014; 14:
7 Wang et al Tillmann HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World J Gastroenterol 2014; 20: Taherkhani R and Farshadpour F. Epidemiology of hepatitis C virus in Iran. World J Gastroenterol 2015; 21: Nguyen DB, Gutowski J, Ghiselli M, et al. A large outbreak of hepatitis C virus infections in a hemodialysis clinic. Infect Contr Hosp Epidemiol 2015; 37: Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: Thomas DL, Leoutsakas D, Zabransky T, et al. Hepatitis C in HIVinfected individuals: cure and control, right now. J Int AIDS Soc 2011; 14: Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: Odari EO, Budambula NL and Nitschko H. Evaluation of an antigenantibody combination enzyme linked immunosorbent assay for diagnosis of hepatitis C virus infections. Ethiop J Health Sci 2014; 24: Aghemo A, Degasperi E, De Nicola S, et al. Quantification of core antigen monitors efficacy of direct-acting antiviral agents in patients with chronic HCV infection. Clin Gastroenterol Hepatol 2016; 14: Ergunay K, Sener B, Alp A, et al. Utility of a commercial quantitative hepatitis C virus core antigen assay in a diagnostic laboratory setting. Diag Microbiol Infect Disease 2011; 70: Mederacke I, Wedemeyer H, Ciesek S, et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009; 46: Medici MC, Furlini G, Rodella A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011; 51: Ross RS, Viazov S, Salloum S, et al. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010; 48:
Received 30 July 2011/Returned for modification 1 September 2011/Accepted 14 September 2011
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 2011, p. 4089 4093 Vol. 49, No. 12 0095-1137/11/$12.00 doi:10.1128/jcm.05292-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationComparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV Antigen test
ORIGINAL ARTICLE May-June, Vol. 13 No. 3, 2014: 337-342 Comparison of two diagnostic algorithms for the identification of patients with HCV viremia using a new HCV Antigen test Miguel Ángel Reyes-Méndez,*
More informationA new automated HCV core Ag assay as an alternative method to. HCV RNA quantification by real-time PCR. Hyon-Suk Kim *
JCM Accepts, published online ahead of print on 29 March 2010 J. Clin. Microbiol. doi:10.1128/jcm.01856-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All
More informationComparison between ELISA and chemiluminescence immunoassay for the detection of Hepatitis C virus antibody
Original Research Article DOI: 10.18231/2394-5478.2017.0078 Comparison between ELISA and chemiluminescence immunoassay for the detection of Hepatitis C virus antibody Pampi Majumder 1, Anup Kumar Shetty
More informationDiagnostic reliability of Architect anti- HCV assay: Experience of a tertiary care hospital in India
Received: 3 February 2017 Accepted: 28 March 2017 DOI: 10.1002/jcla.22245 RESEARCH ARTICLE Diagnostic reliability of Architect anti- HCV assay: Experience of a tertiary care hospital in India Gnanadurai
More informationResearch Article Decision on conducting HCV Immunoblot and HCV Viral Load Tests Dependent upon the Result of the Screening Tests
IBIMA Publishing Journal of Virology & Microbiology http://www.ibimapublishing.com/journals/jvm/jvm.html Vol. 2013 (2013), Article ID 332501, 7 pages DOI: 10.5171/2013.332501 Research Article Decision
More informationARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.
ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What
More informationLearning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016
New HIV Testing Algorithm from CDC ASCLS-Michigan March 31, 2016 Dr. Kathleen Hoag Learning Objectives Following attendance and review of material provided, attendees will be able to: 1. Describe the new
More informationMonitoring of HCV RNA. Hepatitis C Requirements of Antiviral Therapy Monitoring
Monitoring of HCV RNA Hepatitis C Requirements of Antiviral Therapy Monitoring Hepatitis C Requirements of Antiviral Therapy Monitoring Author: Ute Hofmann,, Konrad-Zuse-Str. 1, 07745 Jena, Germany Beatrix
More informationScreening and Diagnosis of Hepatitis Virus Infections
Screening and Diagnosis of Hepatitis Virus Infections Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor
More informationUtility of HCV antigen core quantification for the screening of chronic hepatitis C
Utility of HCV antigen core quantification for the screening of chronic hepatitis C Karine LACOMBE - Léa Duchesne Inserm Unit UMR-S 1136, Team 2 Pierre Louis Institute of Epidemiology and Public Health
More informationThe role of Hepatitis C core Antigen (HCV-cAg) in the era of hepatitis C Direct-Acting Antiretroviral (DAA)
The role of Hepatitis C core Antigen (HCV-cAg) in the era of hepatitis C Direct-Acting Antiretroviral (DAA) Joel Paparello Deputy Charge Nurse HIV Outpatient Services at St Thomas Hospital 214,000&chronically&infected&people&
More information4.9. Monitoring treatment response HCV Decision-making tables PICO 9
4.9. Monitoring treatment response HCV Decision-making tables PICO 9 Monitoring for treatment response using HCV Ag testing in individuals with confirmed active HCV infection: Among individuals receiving
More informationNew HIV Tests and Algorithm: A change we can believe in
New HIV Tests and Algorithm: A change we can believe in Esther Babady, PhD, D (ABMM) Memorial Sloan-Kettering Cancer Center New York, New York Learning Objectives After this presentation you should be
More informationIs Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental Testing?
Original Paper Received: September 1, 2015 Accepted: October 4, 2015 Published online: January 20, 2016 Is Anti-Hepatitis C Virus Antibody Level an Appropriate Marker to Preclude the Need for Supplemental
More informationClinical Infectious Diseases Advance Access published October 9, Hepatitis C core antigen testing: a reliable, quick and potentially
Clinical Infectious Diseases Advance Access published October 9, 2014 1 Hepatitis C core antigen testing: a reliable, quick and potentially cost-effective alternative to Hepatitis C polymerase chain reaction
More informationTechnical Bulletin No. 162
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 162 cobas 6800 HCV Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationHepatitis C Virus Genotype 2 may not be detected by the Cobas AmpliPrep/Cobas. TaqMan HCV Test, version 1.0
JCM Accepts, published online ahead of print on 25 September 2013 J. Clin. Microbiol. doi:10.1128/jcm.02102-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Hepatitis C Virus
More informationAnnex 5.8. PICO 5a and PICO 9 - How to test (confirmation of HCV viraemia)
Annex 5.8 PICO 5a and PICO 9 - How to test (confirmation of HCV viraemia) HCV core antigen testing for presence of active HCV infection and monitoring for treatment response and cure: a systematic review
More informationEpidemiology of HCV infection among HD pts in Iran and prevention strategies
Epidemiology of HCV infection among HD pts in Iran and prevention strategies B. Einollahi Professor of Internal Medicine/Nephrology Division Baqiyatallah University of Medical Sciences 4th International
More informationHepatitis C Virus. https://www.labcorp.com/wps/wcm/connect/labcorp+content/labcorp/education+and+re...
Page 1 of 16 Hepatitis C Virus Data reflected in this report are based solely on the collection of samples submitted to LabCorp for testing. Refer to the limitations section of this report for additional
More informationHuman diagnostics. Better be Sure: Quantify HDV & HBV viral load. RoboGene product family
Human diagnostics Better be Sure: Quantify HDV & HBV viral load. RoboGene product family 2 RoboGene Product Family Improved patient management: Standardized monitoring of HBV DNA and HDV RNA viral load.
More informationHIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)
HIV Update in Laboratory Testing Patricia Slev, PhD, D(ABCC) Objectives Explain the advances in HIV diagnostics, including fourth generation Ag/Ab combination HIV screening assays Describe the new CDC
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationHepatitis C Virus Diagnostics: The Road to Simplification
Hepatitis C Virus Diagnostics: The Road to Simplification Jordan J. Feld, M.D., M.P.H. The ambitious goal of eliminating viral hepatitis as a public health problem by 2030 will require major efforts to
More informationSee external label 2 C-8 C 96 tests CHEMILUMINESCENCE. CMV IgG. Cat # Step (20-25 C Room temp.) Volume
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationUtility of Virological Assays at the DAA Era
Utility of Virological Assays at the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationDiagnostic Methods of HBV infection. Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO)
Diagnostic Methods of HBV infection Zohreh Sharifi,ph.D of Virology Research center, Iranian Blood Transfusion Organization (IBTO) Hepatitis B-laboratory diagnosis Detection of HBV infection involves
More information4th International HIV/Viral Hepatitis Co-Infection Meeting
4th International HIV/Viral Hepatitis Co-Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Assuring access to antiviral therapy for ALL co-infected patients from low to high income settings
More informationThe Alphabet Soup of Viral Hepatitis Testing
The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,
More informationFrequency of HCV, Hbs Ag & HIV in general population Lahore Pakistan
International Journal of Advanced Research in Biological Sciences ISSN: 2348-8069 www.ijarbs.com Volume 3, Issue 8-2016 Research Article Frequency of HCV, Hbs Ag & HIV in general population Lahore Pakistan
More informationGata Haydarpasa Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey; 2
Le Infezioni in Medicina, n. 4, 287-292, 2016 ORIGINAL ARTICLE 287 Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of hepatitis B surface antigen in patients with chronic
More informationHIV Testing Technology and the Latest Algorithm
HIV Testing Technology and the Latest Algorithm David Warshauer, PhD, D(ABMM) Deputy Director, Communicable Diseases Wisconsin State Laboratory of Hygiene HIV Testing has changed over time Patients with
More informationon October 4, 2018 by guest
JCM Accepts, published online ahead of print on 3 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.01249-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 Title: Performance of
More informationPrediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term 2015
THAI J 16 GASTROENTEROL Treatment with Nucleos(t)ide Original Analogues Article Prediction of HBsAg Loss by Quantitative HBsAg Kinetics during Long-Term Treatment with Nucleos(t)ide Analogues Sombutsook
More informationDiagnostic Methods of HBV and HDV infections
Diagnostic Methods of HBV and HDV infections Zohreh Sharifi,ph.D Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine Hepatitis B-laboratory diagnosis Detection
More informationAdvantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform*
Advantages and disadvantages of different types of FDA-approved HIV immunoassays used for screening by generation and platform* HIV immunoassays grouped by generation, platform, and CLIA complexity + Advantages
More informationAnti-Infective Clinical Trials
Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting
More informationTechnical Bulletin No. 161
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 161 cobas 6800 HIV-1 Viral Load Assay - New Platform - June 1, 2017 Contact: Heather Habig, MLS (ASCP) CM, MB CM, 717-851-1422 Operations
More informationRelation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection
Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection xxxxxxxxxxxxxxx Özgür Günal 1, Şener Barut 1, İlker Etikan 2, Fazilet Duygu 1, Umut Tuncel 3, Mustafa
More informationStudy of ChLIA and ELISA for TTI Markers in Blood Donors
Study of ChLIA and ELISA for TTI Markers in Blood Donors Presenting Author - Miss Kiran Kachhadiya (Co-authors: Dr. Vachhani N., Mrs. Bhatt J, Dr. Jani F., Dr. Nandani S.) Life Blood Centre (Formerly known
More informationLaboratory and Clinical Diagnosis of HCV Infection
Laboratory and Clinical Diagnosis of HCV Infection Jean-Michel Pawlotsky,, MD, PhD Department of Virology (EA 3489) Henri Mondor Hospital University of Paris XII Créteil,, France I Nonspecific Liver Tests
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK West of Scotland Specialist Virology Centre New Lister Building Level 5 Glasgow Royal Infirmary 10-16 Alexandra Parade Glasgow G31 2ER Contact:
More information4.6. How to test - testing strategy HCV. Decision-making tables PICO 4
4.6. How to test - testing strategy HCV Decision-making tables PICO 4 Testing strategy to ascertain exposure to HCV: Among persons identified for hepatitis C testing, what is the best testing strategy
More informationQUANTITATIVE HEPATITIS C VIRUS (HCV) RNA
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA Policy Number: PDS - 028 Effective Date:
More information2018 HIV and HCV Diagnostic Testing Survey
2018 HIV and HCV Diagnostic Testing Survey This survey is designed to capture the 2017 HIV and HCV testing practices in state and local public health laboratories (PHL). The results of the survey will
More informationFrequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.
Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationDiagnosis of Acute HCV Infection
Hepatitis C Online PDF created December 20, 2017, 7:54 pm Diagnosis of Acute HCV Infection This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection Lesson
More informationSojan George Kunnathuparambil, Kattoor Ramakrishnan Vinayakumar, Mahesh R. Varma, Rony Thomas, Premaletha Narayanan, Srijaya Sreesh
Original article Annals of Gastroenterology (2013) 26, 1-5 Bilirubin, aspartate aminotransferase and platelet count score: a novel score for differentiating patients with chronic hepatitis B with acute
More informationHepatitis C Best Practice Guidelines For Local Health Departments
Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have
More informationHepatitis C Virus (HCV) Antibody Test
Hepatitis C Virus (HCV) Antibody Test Instructions For Use Format: Cassette For: Catalog Number: VEL-001-HCV Specimen: Serum/Plasma * Please read the instructions carefully before use INTENDED USE Hepatitis
More informationHEPATITIS C VIRUS (HCV) GENOTYPE TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HEPATITIS C VIRUS (HCV) GENOTYPE TESTING Policy Number: PDS - 027 Effective Date:
More informationA multi-center clinical study comparing Sansure Magb and CAP/CTM HBV tests in the quantitative detection of HBV DNA
Original Article A multi-center clinical study comparing Sansure Magb and CAP/CTM HBV tests in the quantitative detection of HBV DNA Xiaoyu Fu 1,Deming Tan 1, Xiaoguang Dou 2,Jinjun Chen 3,Juan Wu 1 1
More informationP0078 SeraQ ARCHITECT P0078
P0078 SeraQ ARCHITECT P0078 The kit insert contains a detailed protocol and should be read carefully before testing the run control to ensure optimal performance Table of contents Intended Use... 3 Key
More informationHIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch
HIV Test Technologies, Best Practices, and New Algorithm Jenny R. McFarlane DSHS HIV Prevention and Care Branch Testing History 1985 1 st Gen HIV-1 IA 1987 HIV-1 WB 1990 HIV-2 IA HIV-1 IA DBS 1991 2 nd
More informationTrends in molecular diagnostics
Trends in molecular diagnostics Detection of target genes of interest Quantification Infectious diseases HIV Hepatitis C & B TB / MAC Cytomegalovirus Herpes simplex Varicella zoster CT/GC HPV Profiling
More informationHepatitis C. Core slides
Hepatitis C Core slides This material was prepared by the Viral Hepatitis Prevention Board The slides (or subsets) can be reproduced for educational use only, with reference to the original source and
More informationRealLine HIV quantitative Str-Format
Instructions for use DETECTION AND QUANTIFICATION OF THE HUMAN IMMUNODEFICIENCY VIRUS RNA BY REAL TIME PCR Research Use Only (RUO) Attention! Please read the information about quantification process carefully!
More informationInternational Journal of Pharma and Bio Sciences DETECTION OF HEPATITIS B SURFACE ANTIGEN USING ELISA AND REAL TIME PCR ABSTRACT
Research Article Biotechnology International Journal of Pharma and Bio Sciences ISSN 0975-6299 DETECTION OF HEPATITIS B SURFACE ANTIGEN USING ELISA AND REAL TIME PCR ALI MOHAMMED ABDUL MOHSEN Indian academy
More informationWhats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen
Whats new on HBsAg and other markers for HBV infection? Christoph Höner zu Siederdissen Why diagnostic markers are important They are the basis for clinical decision makings treatment or no treatment?
More informationPolymerase Chain Reaction and Enzyme-Linked Immunosorbent Assay as Diagnostic Tools for Detection of Hepatitis B Virus Infection, KHMC Experience
Polymerase Chain Reaction and Enzyme-Linked Immunosorbent Assay as Diagnostic Tools for Detection of Hepatitis B Virus Infection, KHMC Experience Rame Khasawneh MD*, Bahieh al-abbadi MD*, Asim Al-Momani
More informationThe impact of the treatment of HCV in developing Hepatocellular Carcinoma
The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University
More informationA Summary of Clinical Evidence
A Summary of Clinical Evidence Supporting the use of the Alere Determine HIV-1/2 Ag/Ab Combo Rapid Test to assist in the diagnosis of Human Immunodeficiency Virus (HIV) TAP HERE TO SEE THE PRODUCTS Table
More informationInfectious Disease Testing. ULTRA Product Line. Safety is not a Matter of Chance
Infectious Disease Testing ULTRA Product Line Safety is not a Matter of Chance ULTRA Product Line The best answer for HBV, HCV and HIV screening: a global automated solution for safe results. Monolisa
More informationBringing quantitative HBsAg to the US provider, drug development and patient network
Bringing quantitative HBsAg to the US provider, drug development and patient network Presenter Robert G Gish MD Adjunct Professor, Stanford University Medical Director HBV Foundation HBV Forum 3 October
More informationSerology and International units
Serology and International units L. Grangeot-Keros, National Reference Laboratory for Rubella, Virology Department, A. Béclère Hospital, Clamart, France Detection of rubella-specific IgG antibody Assays
More informationHIV Serology Quality Assessment Program Summary for Panel HIVS Oct22
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationLife Science Journal 2016;13(1)
HBsAg Serum Level And Viral Load In Egyptian HBV-Infected Patients: Is There A Correlation? El-Sayed Tharwa 1, Mohamed Elmazaly 1, Omkolsoum Elhadad 1, Mohsen Salama 1 and Olfat Hendy 2 1 Departments of
More informationDEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE
DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA - UPDATE SoGAT Clinical Diagnostics III 12-13 January 2011, London Michael Chudy Julia Kreß Micha Nübling Paul-Ehrlich-Institut
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationComparison of MagNA Pure 96, Chemagic MSM1, and QIAamp MinElute for Hepatitis B Virus Nucleic Acid Extraction
370 Comparison of MagNA Pure 96, Chemagic MSM1, and QIAamp MinElute for Hepatitis B Virus Nucleic Acid Extraction Seong-Ho Kang 1, Eun Hee Lee 2, Geon Park 1, Sook Jin Jang 1, and Dae Soo Moon 1 1 Department
More informationOriginal Article Diagnostic Immunology INTRODUCTION https://doi.org/ /alm
Original Article Diagnostic Immunology Ann Lab Med 2017;37:248-253 https://doi.org/10.3343/alm.2017.37.3.248 ISSN 2234-3806 eissn 2234-3814 Comparison of the QIAGEN artus HBV QS-RGQ Assay With the Roche
More informationGlobal reporting system for hepatitis (GRSH) data approval manual
Global reporting system for hepatitis (GRSH) data approval manual Contents Acknowledgement... 1 General information... 2 1. Logging in... 2 2. Validating aggregated numbers in the reports application...
More informationHepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, :00 pm 1:00 pm
Hepatitis C Virus (HCV) & Infectious Disease 101 for Hubs & Spokes April 24, 2018 12:00 pm 1:00 pm Presenters: Thomas E. Freese, PhD, Larissa Mooney, MD, & Rachel McLean, MPH, Chief, Office of Viral Hepatitis
More informationHIV SCREENING WORKSHOP Exercise
HIV SCREENING WORKSHOP Exercise INTRODUCTION: Since its first discovery in 1981, AIDS became a pandemic. Worldwide, actually over 30 million people are living with HIV (i.e., are infected by the human
More informationSupplementary Online Content
Supplementary Online Content Peters PJ, Westheimer E, Cohen S, et al. Screening yield of HIV antigen/antibody combination and pooled HIV RNA testing for acute HIV infection in a high-prevalence population.
More informationThe cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P
The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets
More informationPrise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques
Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationSee external label 2 C-8 C 96 tests Chemiluminescence. CMV IgM. Cat # Diluted samples, controls & calibrator 100 µl 30 minutes
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationRobert G. Gish MD UC San Diego
Robert G. Gish MD UC San Diego The Pipeline of HIV-Related Point-Of- Care Tests is Growing Viral detection Examples: 2012 2013 2014 2015 2016 2017 CD4 test Examples: 2009 2010 2011 2012 2013 0 2014 Evidence
More informationMolecular Diagnosis Future Directions
Molecular Diagnosis Future Directions Philip Cunningham NSW State Reference Laboratory for HIV/AIDS & Molecular Diagnostic Medicine Laboratory, SydPath St Vincent s Hospital Sydney Update on Molecular
More informationPrevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD
Prevent Hepatocellular Carcinoma through Screening, Vaccination, and Treatment of Viral Hepatitis Milena Gould Suarez, MD Hello, my name is Milena Gould Suarez, and today I will present "Prevent Hepatocellular
More informationJournal of Virological Methods
Journal of Virological Methods 157 (2009) 8 14 Contents lists available at ScienceDirect Journal of Virological Methods journal homepage: www.elsevier.com/locate/jviromet A new sensitive and automated
More informationDiagnostic Tests for HIV
Mountain West AIDS Education and Training Center Diagnostic Tests for HIV David Spach, MD Principal Investigator, Mountain West AETC Professor of Medicine, University of Washington Last Updated: June 22,
More informationJMSCR Vol. 03 Issue 06 Page June 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x ImmunoComb II Test in Detection of HCV Antibodies in Oral Fluid Authors Mohamed A Mansour 1,MD; Heba M Abdella 1,MD; Eman A Al Gouhary
More informationKhalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia
1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples
More informationPoint-of-care testing and other new diagnostics for HCV
Point-of-care testing and other new diagnostics for HCV Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto Disclosures Consulting: Abbvie,
More informationHepatitis C: Surveillance, Case Definition, and Investigation
Hepatitis C: Surveillance, Case Definition, and Investigation Tuesday, November 14, 2017 10am 11:30am NJ Department of Health Communicable Disease Service Welcome to the Webinar Today s webinar is being
More informationHTLV Serology Quality Assessment Program Summary for Panel HTLS Oct22
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory HTLV Serology Quality Assessment Program Summary for Panel HTLS425 2015Oct22
More informationWHO Prequalification of In Vitro Diagnostics Programme
WHO Prequalification of In Vitro Diagnostics Programme International HIV/Viral Hepatitis Co-Infection Satellite Meeting 19 July 2014, Melbourne Anita Sands Prequalification Diagnostics Team Department
More informationHBV Core and Core-Related Antigen Quantitation in Chinese Patients with. Chronic Hepatitis B Genotype B and C Virus Infection
Title page HBV Core and Core-Related Antigen Quantitation in Chinese Patients with Chronic Hepatitis B Genotype B and C Virus Infection Short Title: Quantitation of HBc and HBcrAg in Chinese patients Akinori
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationHIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19
National Laboratory for HIV Reference Services National HIV and Retrovirology Laboratories National Microbiology Laboratory Public Health Agency of Canada HIV Serology Quality Assessment Program Summary
More informationHigh Rate of Missed HIV Infections in Individuals With Indeterminate or Negative HIV Western Blots Based on Current HIV Testing Algorithm in China
Journal of Medical Virology 88:1462 1466 (2016) High Rate of Missed HIV Infections in Individuals With Indeterminate or Negative HIV Western Blots Based on Current HIV Testing Algorithm in China Man-Qing
More informationGuidance for Industry
Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test
More informationCADTH HEALTH TECHNOLOGY ASSESSMENT Screening for Hepatitis C Virus: A Systematic Review
CADTH HEALTH TECHNOLOGY ASSESSMENT Screening for Hepatitis C Virus: A Systematic Review PROSPERO Registration Number: CRD42015029568 Service Line: Health Technology Assessment Issue Number: 144 Version:
More information4th International HIV/Viral Hepatitis Co- Infection Meeting
INSTITUTIONAL STRAPLINE 4th International HIV/Viral Hepatitis Co- Infection Meeting The Rocky Road to Viral Hepatitis Elimination: Approaches for simplified HCV diagnostics and screening algorithms: thoughts
More information